Key result
Droxidopa and midodrine consistently improved orthostatic symptoms and are recommended as first-line therapies for orthostatic hypotension, while atomoxetine and fludrocortisone demonstrated moderate efficacy.
Why the study?
Orthostatic hypotension is a debilitating condition associated with increased morbidity and mortality, warranting evaluation of the efficacy and safety of pharmacological treatments.
Do pharmacological interventions improve symptoms and blood pressure in adults with neurogenic orthostatic hypotension?
Systematic Review
Do pharmacological interventions improve symptoms and blood pressure in adults with neurogenic orthostatic hypotension?
Answers are grounded in this paper and cite their sources.
Pharmacological treatments like droxidopa and midodrine are effective first-line therapies for neurogenic orthostatic hypotension, though adverse effects like supine hypertension require personalized management.
Orthostatic hypotension (OH), defined as a sustained drop in systolic (≥20 mmHg) or diastolic (≥10 mmHg) blood pressure upon standing, is a debilitating condition prevalent in older adults and individuals with neurodegenerative disorders. It significantly impacts quality of life, leading to dizziness, falls, and syncope, and is associated with increased morbidity and mortality. This systematic review evaluates the efficacy and safety of pharmacological treatments for OH. Following the PRISMA 2020 guidelines, 25 studies, including randomized (RCTs) and non-randomized controlled trials (NRCTs), were analyzed. Study quality was assessed using the Cochrane Risk of Bias 2 (ROB 2) tool, the Joanna Briggs Institute (JBI) Checklist, and the Newcastle-Ottawa Scale (NOS). The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was applied to evaluate the certainty of evidence across key outcomes. Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies. Atomoxetine and fludrocortisone showed moderate efficacy, while pyridostigmine in combination therapies provided additional benefits. Octreotide demonstrated potential for refractory OH but lacked robust evidence. Adverse effects, including supine hypertension, dizziness, gastrointestinal disturbances, and fatigue, highlight the need for personalized therapy to balance efficacy and tolerability. While pharmacological treatments show promise, further comparative and long-term studies are necessary to refine therapeutic strategies and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Saraya et al. (2025) conducted a systematic review in Orthostatic hypotension. Pharmacological interventions (droxidopa, midodrine, atomoxetine, pyridostigmine, fludrocortisone, octreotide) vs. Placebo or active comparator was evaluated on Improvement in orthostatic symptoms and standing blood pressure. Droxidopa and midodrine consistently improved orthostatic symptoms and are recommended as first-line therapies for orthostatic hypotension, while atomoxetine and fludrocortisone demonstrated moderate efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: